

Original article

Brachiobasilic arteriovenous fistula with superficialisation and transposition the basilic vein in a one stage surgical technique. Five years of single experience[☆]

Néstor Fontseré^{a,*}, Gaspar Mestres^b, Xavier Yugueros^b, Mario Jiménez^a, Marta Burrel^c, Fernando Gómez^c, Raquel Ojeda^a, Lida María Rodas^a, Valentín Lozano^a, Vicens Riambau^b, Francisco Maduell^a

^a Servicio de Nefrología, Hospital Clínic, Unidad Funcional de Acceso Vascular, Barcelona, Spain

^b Servicio de Cirugía Vascular, Hospital Clínic; Unidad Funcional de Acceso Vascular, Barcelona, Spain

^c Servicio de Radiología Vascular Intervencionista, Hospital Clínic, Unidad Funcional de Acceso Vascular, Barcelona, Spain

ARTICLE INFO

Article history:

Received 27 March 2018

Accepted 25 November 2018

Available online 15 September 2019

Keywords:

Haemodialysis

Vascular access

Basilic-humeral arteriovenous fistula

Single-stage surgical technique

ABSTRACT

Background: The basilic vein is a deep vein which usually requires superficialisation and surgical transposition.

Material and methods: This is a retrospective study of 119 BBAVF-ST in patients with stage 5D chronic kidney disease who received an implant with a one-stage surgical technique (2011–2015). The percentage of primary (PP), assisted primary (APP) and secondary (SP) permeabilities were assessed, as well as the related complications. We analyzed the permeabilities using Kaplan–Meier survival curves and a univariate Log Rank analysis (Mantel–Cox). *p* values less than or equal to 0.05 were considered as significant.

Results: The mean age of the study group was 67.9 years, with 63.8% of the subjects being male. A total of 57 complications were detected during the follow-up period: 24 stenosis (42.1%), 11 thrombosis (19.2%), 7 vascular access steal syndromes (12.2%), 7 upper limb oedemas (12.2%), 6 post-puncture haematomas (10.5%) and 2 infections (3.5%). The percentages of PP obtained at 1, 6, 12 and 24 months were 92.4%, 79.8%, 66.3% and 52%; APP: 94.1%, 87.3%, 80.4% and 65.6%, and SP: 95%, 89.1%, 84% and 67.5%, respectively. Diabetic patients presented with significantly worse permeabilities than vascular or idiopathic patients: (*p* = .037, .009 and .019, respectively).

Conclusions: According to the results obtained in our study, the one-stage surgical implementation of BBAVF-ST presents high permeability rates and a small number of related complications. Diabetes mellitus is a factor related to a worse surgical prognosis. Some of

DOI of original article:

<https://doi.org/10.1016/j.nefro.2018.11.010>.

^{*} Please cite this article as: Fontseré N, Mestres G, Yugueros X, Jiménez M, Burrel M, Gómez F, et al. Fístulas arteriovenosas nativas humerobasilicas con superficialización y trasposición en un solo acto quirúrgico. Revisión de cinco años de experiencia. Nefrología. 2019;39:388–394.

^{*} Corresponding author.

E-mail address: fontseren@clinic.cat (N. Fontseré).

2013-2514/© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

the biggest advantages are the greater optimization of health resources and a shorter time in which the central venous catheter needs to remain in the body.

© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Fístulas arteriovenosas nativas humerobasílicas con superficialización y trasposición en un solo acto quirúrgico. Revisión de cinco años de experiencia

R E S U M E N

Palabras clave:

Hemodiálisis
Acceso vascular
Fístula arteriovenosa nativa
humerobasílica
Un solo acto quirúrgico

Introducción: La vena basílica se caracteriza por ser un vaso profundo que en la mayoría de los casos requiere superficialización y trasposición quirúrgica.

Material y métodos: Estudio retrospectivo de 119 FAVn HB S-T en pacientes con insuficiencia renal crónica 5D implantadas en un solo acto quirúrgico (2011-2015). Se analiza el porcentaje de permeabilidades primaria (PP), primaria asistida (PPA) y secundaria (PS), así como las complicaciones asociadas. Análisis de permeabilidades mediante curvas de supervivencia Kaplan-Meier y análisis univariante mediante Log Rank (Mantel-Cox). Se considera significativa una $p \leq 0,05$.

Resultados: Edad media 67,9 años y 63,8% hombres. Durante el período de seguimiento se objetivaron un total de 57 complicaciones: 24 estenosis (42,1%), 11 trombosis (19,2%), 7 síndromes de robo vascular (12,2%), 7 edemas de extremidad superior (12,2%), 6 hematomas postpunción (10,5%) y 2 infecciones (3,5%). Los porcentajes de PP obtenidos a 1, 6, 12 y 24 meses: 92,4, 79,8, 66,3 y 52; PPA: 94,1, 87,3, 80,4 y 65,6%, y PS: 95, 89,1, 84 y 67,5%. Se constataron diferencias significativas en las curvas de PP, PPA y PS según la etiología, presentando peores permeabilidades los diabéticos respecto a la vascular e idiopática ($p = 0,037$, $0,009$ y $0,019$).

Conclusiones: La implantación quirúrgica de FAVn HB S-T en un solo acto ofrece buenas tasas de permeabilidad y escaso número de complicaciones asociadas. La diabetes mellitus representa un factor de peor pronóstico quirúrgico. Entre las mayores ventajas destacan una mejor optimización de los recursos sanitarios y menor tiempo de permanencia del catéter venoso central.

© 2019 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Different studies have shown that hemodialysis patients with native arteriovenous fistulas (NAVF) have more dose of dialysis, a long period of patency and less complications.¹⁻³ By contrast, patients with central venous catheters show worse survival curves, due to a greater morbidity and mortality due to infections.⁴⁻⁶

According to the recommendations of the current Spanish Vascular Access Guidelines,⁷ the placement of an AVF as distal as possible should be the first surgical option. However, in some patients in whom the placement of a radiocephalic or humerocephalic AVF is not feasible, the placement of more proximal accesses should be a third or fourth surgical option as an alternative to the placement of a vascular prosthesis.⁸

Dagher et al.⁹ were the first surgeons to describe in 1976 the use of this type of AVF as vascular access for patients in regular hemodialysis. The basilic vein is characterized by having of good caliber but in most cases it is deep when placed in a deep plane to the aponeurotic tissue. In addition,

this vascular structure runs adjacent to the vascular and nervous bundle of the arm, so superficialization of the vein and its transposition is recommended to move away from the surgical wound, avoiding fibrosis and facilitating its cannulation after completion of the maturation process.

In the current vascular guidelines, there is no consensus to recommend implantation in one or two surgical procedures.^{7,10,11} The main advantage of a single step procedure is to shorten the time required to start the cannulation and the possibility to remove the central venous catheter. However, in some cases, mechanical complications during the surgical procedure could occur with the mobilization of a non-arterialized vein. Some authors claim that, if performed in two stages, the vein could have increased the length which facilitate superficialization with less intraoperative complications. This second stage forces either to ligate the previous anastomosis and do it again after superficialization, or to cut sensitive branches. nervous that run over the basilic vein.

The main objective of the present study is to analyze our experience in the surgical placement of humerobasilic nFAV

with superficialization and transposition in a single surgical act.

Objectives

Primary objective. To analyze our results in the implantation of humero-basilic nAVF with superficialization and transposition in a single surgical act: patency rates (primary, primary assisted and secondary) and associated complications during the follow-up period. **Secondary objective.** Study possible relationships between patency rates and different sociodemographic or comorbidity factors.

Methods

The Functional Unit of Vascular Access of the Hospital Clínic is a transversal and multidisciplinary structure for the management of vascular access of patients in different areas of Catalonia (nephrology, vascular surgery and angiorradiology). All endovascular and surgical procedures are recorded in our database. The present study, is an observational and retrospective analysis of 119 humerobasilic fistulas that were superficialized and transposed in a single surgical act (HB ST nAVF) out of a total of 1.676 interventions performed between 2011 and 2015. The follow-up period lasted until December 31, 2017; transplant patients and those who have died were collected. Different variables were recorded: (a) Cardiovascular risk (hypertension, diabetes, ischemic heart disease, dyslipidemia, cerebrovascular accident or peripheral

vascular disease); (b) Antiplatelet or anticoagulant treatment; (c) Presence of ipsilateral central venous catheter or contralateral pacemaker, and (d) Pre-surgical echographic parameters (diameter of basilic vein and humeral artery). Each patient was evaluated in our outpatient clinic by different specialists including an exhaustive and systematic physical examination and eco-Doppler (mapping). The HBV S-T nAVF was performed in patients with no possibility to have distal (radio-cephalic) accesses because of an arterial and or vein diameter <2 mm or more proximal (humerocephalic) due to a sclerosed vein or with a diameter <3 mm. In these cases, if the proximal basilic vein is permeable, with enough caliber (>3 mm) and well connected with the deep venous system, as well as a suitable artery (greater than 2.5 cm in diameter) diameter and with three-phase Doppler curve, we chose to perform this type of access, and only occasionally forearm prosthetic loops.

Normally the HB S-T nAVF is performed as an outpatient. The patient comes to the hospital the same day of surgery, and is discharged 1-2 h observation post-surgery. The surgical procedure is performed under regional anesthesia, by echo guided axillary plexus blockade. Briefly, the surgical act consists in dissecting the basilic vein by means of two longitudinal incisions in the anterior aspect of the arm (instead of a long one, to minimize the complications of the wound). The basilic vein is tunneled through the anterior side of the arm making a curve (to avoid fibrosis of the surgical wounds on the vein), after demonstration of its permeability with physiological saline solution, the vein is anastomosed end-to-side with the humeral artery. The presence of pulse and thrill in the vein is confirmed intraoperatively, as well as its correct




Fig. 1 – Surgical procedure of implantation of a native humerobasilica FAV with superficialization and transposition in a single surgical act. Dissection of the basilic vein by means of two complementary incisions (A), tunneling in the anterior subcutaneous plane (B), arteriovenous anastomosis (C) and final appearance after closure of surgical wounds (D).

permeability by Doppler ultrasound and the absence of distal ischemic events. After a brief observation period (1–2 h) the patient is discharged and monitored on an outpatient basis. Fig. 1 shows each of the surgical steps graphically.

Definitions

- *Primary permeability (days)*. It is defined as the period of time elapsed since the placement of the HB S-T nAVF and the need to apply any endovascular or surgical technique to maintain the permeability of the vascular access.
- *Assisted primary permeability (days)*. It is defined as the period of free time elapsed since the placement of the HB S-T nAVF and the appearance of thrombosis.
- *Secondary permeability (days)*. It is defined as the period of time elapsed since the surgical placement of the HB S-T nAVF and the loss of vascular access (thrombosis not recanalizable). Transplanted patients, those lost in follow-up and those who died have been considered as censored cases for the three permeabilities.
- *Initial surgical success*. HB S-T nAVF functioning with manifest pulse, continuous murmur and presence of thrill after completion of the surgical procedure.
- *Adequate maturation*. It is defined by clinical and ultrasound criteria as described by latest Spanish Vascular Access Guidelines.⁷

The statistical analysis included descriptive techniques, chi-square test for proportions and Student's t for continuous variables, using the statistical package SPSS v21 (IBM Corp, Armonk, NY). Kaplan–Meier survival curves were used to estimate the rates of primary, assisted primary and secondary patency during follow-up. An univariate analysis was performed using Log Rank analysis (Mantel–Cox) to compare how permeabilities are affected by main prognostic factors of permeability (sex, age over 70 years, etiology, hypertension, dyslipidemia, ischemic heart disease, antiaggregant treatment or of previous central venous catheter); variables present in less than 5% of the sample (pacemaker, anticoagulation, peripheral vasculopathy, stroke) and in those with subcategories with less than 5% representation (etiology) were excluded from the analysis. The etiologies were grouped as diabetic, vascular, idiopathic etiology and other etiologies. The permeabilities estimated at 2 years are described. A $p \leq 0.05$ is considered significant.

Results

A total of 119 patients with chronic kidney failure stage 5D were included, all patients had the placement of HB S-T nAVF. Mean age of 67.9 ± 14.2 years (21–91), 63.8% were males. The causes of kidney failure were diabetes mellitus (31.1%), vascular disease (46.2%) and idiopathic (15.1%). A surgical success was achieved in 97.4% of the patients and adequate maturation was observed in 89.1%. Table 1 summarizes the demographic and clinical description of the patients included. During the follow up period, 12 patients were transplanted and 11 died (all of them with functioning fistulas), and the follow up was not completed in 26 patients and were

Table 1 – Main sociodemographic and comorbidity factors of the study group.

Variable	n and (%) or mean \pm SD (range)
Sex (males/females)	76/43
Average age (years)	67.9 ± 14.2 (21–91)
Hypertension	96 (81%)
Mellitus diabetes	37 (31%)
Dyslipidemia	44 (37%)
Ischemic heart disease	14 (11.8%)
Vascular-cerebral accident	6 (5%)
Peripheral vascular disease	2 (1.7)
Antiaggregant treatment	25 (21%)
Anticoagulant treatment	5 (4.2%)
Previous central venous catheter	14 (11.8%)
Pacemaker	3 (2.5%)
Previous FAVn, mean (range)	2.4 (1–4)
Diameter basilic vein (mm)	4.01 ± 1.00 (2–7.5)
Diameter humeral artery (mm)	3.9 ± 0.8 (2.4–8)

considered losses. The mean(SD) follow-up was 888 (601)days. During the follow-up period, there were a total of 57 complications: stenosis $n=24$ (42.1%), thrombosis $n=11$ (19.2%), vascular steal syndromes $n=7$ (12.2%), edema of the upper extremity $n=7$ (12.2%), post-puncture hematomas $n=6$ (10.5%) and infections $n=2$ (3.5%). Regarding the location of the stenosis, in 9 cases affected the first portion of the efferent vein that were treated with 8 angioplasties and one surgical re-anastomosis), 9 cases in the first venous portion and the middle third (8 angioplasties and one surgical repair), 4 cases in the innominate trunk (4 angioplasties) and 2 at the level of the proximal one third and axillary vein (2 angioplasties).

The percentages of primary permeability (PP) estimated with Kaplan Meier survival curves, at 1, 3, 6, 12, 18 and 24hr months were 92.4, 89.1, 79.8, 66.3, of 57.3 and 52.0%. The assisted primary permeability (APP) was 94.1, 92.4, 87.3, 80.4, 73.0% and 65.6%, and the percent of secondary permeability (SP), were 95.0, 93.3, 89.1, 84.0, 75.9 and 67.5%, respectively.

Comparison of permeability curves (PP, PPP and PS) during follow-up showed that among the possible prognostic factors (sex, age over 70 years, etiology, hypertension, dyslipidemia, ischemic heart disease, antiplatelet therapy or use of a previous central venous catheter), only significant differences were found among the different etiologies of renal failure, for the three survival estimates. A worse survival was observed for other etiologies and diabetics than for vascular (nephroangiosclerosis) or idiopathic etiology.

At 12 and 24 months, in diabetics, vascular, idiopathic and other etiology groups, respectively, the permeabilities were: PP: 55.1–29.0%, 76.4–65.7%, 72.2–59.6% and 41.7–15.6% ($p=0.037$ Log Rank-Mantel–Cox); APP: 78.6–57.3%, 85.5–75.2%, 83.3–68.4% and 58.3–25.9% ($p=0.009$), and SP: 82.2–58.9%, 89.1–76.8%, 83.3–68.8% and 66.7–31.7% ($p=0.019$, Fig. 2). However, the analysis of subcategories only showed worse primary permeabilities, for the grouping of diabetic etiologies and others vs vascular and idiopathic ($p=0.01$, $p=0.062$ and $p=0.062$). No significant differences were observed in assisted primary permeability or secondary permeability. The rest of the risk factors, such as the cases with central venous catheters, showed no significant differences (Table 2).




Fig. 2 – Survival curves (Kaplan–Meier) analyzing primary, assisted primary and secondary patency, according to the etiology: diabetes mellitus, vascular pathology (nephroangiosclerosis), idiopathic and others.

Table 2 – Estimates (%) of primary patency (PP), assisted primary patency (APP) and secondary (SP), at two years of follow-up, for the different prognostic factors, standard deviation (SD) and statistical significance of the differences between groups (P).

	PP			APP			SP		
	%	SD	p	%	SD	p	%	SD	p
Age									
<70 years old	51.5	0.065	0.875	67.7	0.064	0.865	69.7	0.062	0.929
>Age70	50.0	0.070		60.7	0.068		62.7	0.067	
Sex									
H	55.3	0.058	0.856	70.7	0.054	0.324	71.2	0.053	0.462
M	42.3	0.082		52.3	0.085		56.0	0.087	
Etiology									
DM	29.0	0.081	0.037	57.3	0.091	0.009	58.9	0.089	0.019
NAE	65.7	0.067		75.2	0.060		76.8	0.059	
Idiopathic	59.6	0.119		68.4	0.121		68.8	0.120	
Other	15.6	0.131		25.9	0.144		31.7	0.164	
Dyslipidemia									
Do not	52.2	0.059	0.771	63.1	0.058	0.246	65.9	0.058	0.238
Yes	48.9	0.081		66.5	0.077		66.9	0.076	
Cardiopathy									
Do not	52.4	0.051	0.587	65.7	0.049	0.537	67.9	0.048	0.656
Yes	39.7	0.136		57.1	0.132		57.1	0.132	
Antiaggregant									
Do not	53.8	0.053	0.240	67.9	0.051	0.705	69.1	0.050	0.882
Yes	37.4	0.109		50.3	0.110		54.0	0.112	
Previous CVC									
Do not	50.1	0.051	0.784	65.6	0.049	0.745	67.7	0.049	0.582
Yes	56.3	0.135		56.3	0.135		56.3	0.135	
Side									
Straight	49.1	0.079	0.592	63.6	0.075	0.640	63.6	0.075	0.362
Left	52.3	0.060		65.0	0.059		68.0	0.058	
Hypertension									
No	57.7	0.110	0.505	60.1	0.113	0.999	60.6	0.113	0.841
Yes	49.3	0.053		65.4	0.051		67.7	0.050	

Discussion

This study demonstrates that surgical implantation of humero-obasiliac FAVn with superficialization and transposition in a

single surgical act results in good patency rates with few complications during the follow-up period. If this intervention is performed in a single time, the basilic vein is dissected and mobilized, then the new path is created followed by the

Table 3 – Comparative analysis of the permeabilities (primary and secondary) obtained in the main studies (1 and 2 surgical acts).

Studies	Number procedures (subtype)	Primary P.		Secondary P.	
		1 year	2 years	1 year	2 years
Ozcan et al. ¹⁷	106				
	1 step: 47	70%	64%	76%	72%
Vrakas et al. ¹⁸	2 steps: 59	84%	73%	90%	82%
	149				
Agarwal et al. ¹⁹	1 step: 65	71%	53%	79%	57%
	2 steps: 84	87%	75%	95%	77%
Fontseré et al.	144				
	1 step: 61	82%	81%	91%	80%
Fontseré et al.	2 steps: 83	67%	27%	81%	61%
	119				
Fontseré et al.	1 step: 119	66%	52%	84%	67%

arteriovenous anastomosis. The main advantage of a single procedure is the greater speed in the cannulation of the vascular access and the shorter period of time of permanence of the central venous catheter, minimizing the risk of endovascular infections. The disadvantage lies in having as possible complications a greater number of mechanical problems related to the superficialization and transposition of a non-arterialized vein.

Some authors propose that the placement of this type of vascular access should be performed in a two steps procedure. First perform, the anastomosis between the basilic vein and the humeral artery, and 30–90 days later, perform superficialization and/or transposition when an adequate maturation is evidenced by echography.¹² The publications describe three possible techniques for the superficialization of the basilic vein: (a) anterior transposition in the arm, by creating a new subcutaneous tunnel; (b) Anterior transposition in the arm by creating a lateral flap of skin and subcutaneous tissue and, (c) simple superficialization without transposition, although in this case it is difficult for the nursing staff to puncture.

Several studies have shown better survival curves with superficialization of the basilic vein versus the implantation of prosthetic fistulas (pAVF).^{13,14} Among the complications associated with grafts, it should be mentioned the neointimal hyperplasia of the vein, mainly at the level of the venous anastomosis, with thrombosis and infection. According to some studies, up to 90% of the patients who presented thrombosis of their pAVF have hyperplasia of the venous neointima that causes significant stenosis.¹⁵ This is important when deciding which type of vascular access to implant, especially in older patients with associated comorbidities.

A recent meta-analysis based on 8 studies including 859 HB S-T nAVF (366 single-procedure and 493 two surgical acts) concludes that there are no significant differences in terms of maturation rates, postoperative complications and permeabilities (PP, APP and SP).¹⁶ Studies reporting surgical complications in one act vs two surgical acts show adequate maturation (90–20% vs 95–18%), postoperative hematomas (17–4% vs 25–3%) and infections (18–0% vs 15–0%). As compared with other series we have a low rate of immediate postoperative complications (bruising, reoperation due to bleeding, infections or immediate thrombosis), results that support the safety of a single surgical act.

As far as permeability, there is a tendency in favor of the two vs one surgical acts, although without reaching statistical significance.¹⁶ Table 3 compares the results from some of the main studies. In our series, permeabilities obtained (PP and SP) were similar to those reported in a single surgical act but lower than in the two acts. It should be noted that, according to the results obtained in a recent meta-analysis,²⁰ diabetes mellitus predicts poor survival of the AVF. In this sense, our study has shown that patient's pathology is the only predictive variable of permeability (primary, primary and secondary) during follow-up. Table 2 shows the permeabilities at 2 years of follow-up: given the high number of censored patients and events during follow-up, we consider the two years an adequate time point to describe differences. And although the etiologies are varied (etiologies have been grouped with less than 5% representation in "other" etiologies, which are not analyzed in detail given their heterogeneity), it was found a different distribution of all permeabilities according depending on the etiology.

According to our results diabetic patients and other etiologies presented worse permeabilities at 12 and 24 months than patients with vascular pathology or of unknown etiology (idiopathic). However, the analysis of subcategories only showed worse primary permeabilities, but not primary or secondary, in diabetic and other etiologies. This is probably due to the small number of patients, the high number of losses and events during the follow-up and the heterogeneity of the group of other etiologies (only present in 10% of cases). The reasons why the diabetic patients show worse permeability than vascular and idiopathic pathologies are not completely clear, but it is worth mentioning a greater platelet aggregation and endothelial damage, favoring the thrombosis and loss of vascular access.²¹ On the other hand, it is well known that atherosclerosis is more prevalent in diabetic patients, with more problems of arteries supplying adequate blood flow.^{22,23}

Thus, it is recommended the implementation of an active program of monitoring and early detection of significant vascular access dysfunction based on first and second generation methods (vascular flow measurement).⁷ The differences obtained within our series could be explained on the basis that most patients from other areas of Catalonia were monitored only by first generation methods. Also, it is not always known the prevalence of diabetic patients in other published studies,

a factor that, as we have shown, may have a negative impact on the survival of this type of native vascular access. Finally, unlike other surgical groups, we prioritize the implantation of this type of access even with limited veins available before the creation of a humerus-axillary prosthesis, a reason that may also go against our results. Among the main limitations of our study are that it is not prospective study and lacks a control group with superficialization and transposition of the basilic vein in two surgical steps.

Conclusions

According to the results obtained in the present study, the surgical implantation of S-T HB nAVF in a single surgical act offers good patency rates and a low number of complications. Diabetes mellitus is a factor that predict a worse surgical prognosis based on lower rates of permeability. Among the greatest advantages of this technique are a better optimization of social healthcare resources and a shorter duration of the central venous catheter.

Conflicts of interest

The authors declare that they have no conflicts of interest.

REFERENCES

1. Maduell F, Vera M, Arias M, Fontseré N, Blasco M, Serra N, et al. How much should dialysis time be increased when catheters are used? *Nefrologia*. 2008;28:633-6.
2. Gruss E, Portolés J, Caro P, Merino JL, López-Sánchez P, Tato A, et al. Los modelos de atención al acceso vascular condicionan resultados heterogéneos en los centros de una misma comunidad. *Nefrologia*. 2010;30:310-6.
3. Lerma R, Callejas JM. Accesos vasculares para hemodiálisis: equipos multidisciplinarios. *Angiología*. 2005;57 Suppl. 2:169-76.
4. Roca-Tey R, Arcos E, Comas J, Cao H, Tort J. Catalan Renal Registry Committee Starting hemodialysis with catheter and mortality risk: persistent association in a competing risk analysis. *J Vasc Access*. 2016;17:20-8.
5. Fariñas MC, García-Palomo JD, Gutiérrez-Cuadra M. Infection associated with hemodialysis and peritoneal dialysis catheters. *Enferm Infecc Microbiol Clin*. 2008;26: 518-26.
6. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ. Effect of change in vascular access on patient mortality in hemodialysis patients. *Am J Kidney Dis*. 2006;47:469-77.
7. Ibeas J, Roca-Tey R, Vallespín J, Moreno T, Moñux G, Martí-Monrós A, et al. Spanish clinical guidelines on vascular access for haemodialysis. *Nefrología*. 2017;37 Suppl. 1:1-193.
8. Arenas MD, Gil MT, Malek T, Moledous A, Nuñez C, López-Colado M. Superficialización de accesos venosos autólogos: una alternativa al uso de prótesis vasculares y catéteres permanentes. *Nefrologia*. 2009;29:67-70.
9. Dagher F, Gelber R, Ramos E, Sadler J. The use of basilica vein and brachial artery as an A-V fistula for long term hemodialysis. *J Surg Res*. 1976;20:373-6.
10. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. *Am J Kidney Dis*. 2006;48(Suppl. 1):S1-322.
11. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al. EBPG on vascular access. *Nephrol Dial Transplant*. 2007;22 Suppl. 2:ii88-117.
12. Tan TW, Farber A. Brachial-basilic autogenous access. *Semin Vasc Surg*. 2011;24:63-71.
13. Keuter XH, De Smet AA, Kessels AG, van der Sande FM, Welten RJ, Tordoir JH. A randomized multicenter study of the outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis. *J Vasc Surg*. 2008;47:395-401.
14. Weale AR1, Bevis P, Neary WD, Lear PA, Mitchell DC. A comparison between transposed brachio-basilic arteriovenous fistulas and prosthetic brachioaxillary access grafts for vascular access for hemodialysis. *J Vasc Surg*. 2007;46:997-1004.
15. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. *N Engl J Med*. 2009;360:2191-201.
16. Bashar K, Healy DA, Elsheikh S, Browne LD, Walsh MT, Clarke-Moloney M, et al. One-stage vs. two-stage brachio-basilic arteriovenous fistula for dialysis access: a systematic review and a meta-analysis. *PLOS ONE*. 2015;10:e0120154, <http://dx.doi.org/10.1371/journal.pone.0120154>.
17. Ozcan S, Gür AK, Yener AU, Odabaşı D. Comparison of one- and two-stage basilic vein transposition for arterio-venous fistula formation in haemodialysis patients: preliminary results. *Cardiovasc J Afr*. 2013;24:364-8.
18. Vrakas G, Defigueiredo F, Turner S, Jones C, Taylor J, Calder F. A comparison of the outcomes of one-stage and two-stage brachio-basilic arteriovenous fistulas. *J Vasc Surg*. 2013;58:1300-4.
19. Agarwal A, Mantell M, Cohen R, Yan Y, Trerotola S, Clark TW. Outcomes of single-stage compared to two-stage basilic vein transposition fistulae. *Semin Dial*. 2014;27:298-302.
20. Yan Y, Ye D, Yang L, Ye W, Zhan D, Zhang L, et al. A meta-analysis of the association between diabetic patients and AVF failure in dialysis. *Ren Fail*. 2018;40:379-83.
21. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. *Circulation*. 2003;108:1527-32.
22. Jin DC, Yun SR, Lee SW, Han S-W, Kim W, Park J, et al. Current characteristics of dialysis therapy in Korea: 2016 registry data focusing on diabetic patients. *Kidney Res Clin Pract*. 2018;37:20-9.
23. NFK/DOQI. Clinical practice guidelines for vascular access. *Am J Kidney Dis*. 2006;48 Suppl. 1:S176-273.